SANOFI-ADR
SNYNASDAQTrading Snapshot
- Day Range
- $41.63 โ $42.28
- 52-Week Range
- โ
- Volume (shares)
- 2,909,387
- Avg Volume (shares)
- โ
- Shares Outstanding
- 1.21B
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- $46.72B
- Last Q Revenue
- $12.30B
- P/E Ratio
- 22.5
- P/S Ratio
- 1.8x
- EPS (TTM)
- โ
- Dividend Yield
- 10.90%
- Dilution (1yr)
- โ2.6%
SANOFI-ADR
SNYAbout SANOFI-ADR
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Ratings
โLatest News & Updates

Regeneron's Billion-Dollar Catalyst Flying Under Wall Street's Radar Ahead of Oct. 30 Earnings
Regeneron (NASDAQ:REGN | REGN Price Prediction) reports third-quarter results on Oct. 30. Regeneron books its full share of Dupixent profits from Sanofi (NASDAQ:SNY) for the first time this quarter.

Sanofi: An Alluring And Balanced Mix Of Yield And Growth
Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from โฌ34.7 billion in FY 2016

Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk
Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide sol

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
CAMBRIDGE, England--(BUSINESS WIRE)--ScionxBio (the โcompanyโ, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering

Enable Injections Announces Approval in Japan for CirCLIQยฎ Injector based on enFuseยฎ On-Body Delivery System
Sanofi's CirCLIQยฎ Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma

Press Release: Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its Bio